HONG KONG, Jan. 8, 2024 /PRNewswire/ Akeso, Inc. today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the.
Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients
Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients
Catalyst Events Expected in Q2 2024 for Two Randomized.
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Intensity Therapeutics (INTS) Presents Positive INT230-6 Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.